Thera-SAbDab

ULOCUPLUMAB

>   Structural Summary
TherapeuticUlocuplumab
TargetCXCR4
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGTTVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (August '23)Phase-I%2FII
Estimated Status (August '23)Active
Recorded Developmental Technologyna
INN Year Proposed2013
INN Year Recommended2014
Companies InvolvedBristol-Myers Squibb%3BMedarex%3BUniversity of Bari
Conditions Approvedna
Conditions ActiveAcute myeloid leukaemia%3BSolid tumours%3BWaldenstrom%27s macroglobulinaemia%3BNeuroectodermal tumours
Conditions DiscontinuedB-cell lymphoma%3BB-cell prolymphocytic leukaemia%3BPrecursor cell lymphoblastic leukaemia-lymphoma%3BMultiple myeloma
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy